Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
3
50%
Ph phase_3
1
17%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

NCT04005287
terminatedphase_1

Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

NCT01024842
completedphase_2

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

NCT00885118
completedphase_3

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

NCT01368081
completedphase_2

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

NCT01193218
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04005287Phase 2

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

Completed
NCT01024842Phase 1

Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

Terminated
NCT00885118Phase 2

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Completed
NCT01368081Phase 3

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Completed
NCT01193218Phase 2

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Completed
NCT01251315Phase 1

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6